Back to portfolio

Athira Pharma, Inc.

Clinical stage development of regenerative therapeutics for neurodegenerative disease

Athira has developed a proprietary small molecule platform which repairs neuronal function centrally and in the peripheral nervous system, using a novel regenerative method of action that targets the hepatocyte growth factor (HGF) pathway. Athria's lead compound, NDX-1017, is entering Phase 2 clinical trials and will be rapidly advanced utilizing a capital efficient strategy targeting cognitive enhancement followed by the ultimate goal of disease modification.

Life Sciences
Investment year
Organization type
Related News
Endpoints, June 4, 2020

Can a small biotech successfully tackle an Everest climb like Alzheimer’s? Athira has $85M and some influential backers ready to give it a shot

Global Newswire, September 17, 2020

Athira Pharma Announces Pricing of Initial Public Offering

Global Newswire, December 8, 2020

Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease